close

Fenwick Represents Audentes Therapeutics in Pending $3 Billion Acquisition by Astellas Pharma

December 02, 2019

Volutpat odio facilisis mauris sit amet. Turpis egestas integer eget aliquet. Amet tellus cras adipiscing enim eu turpis. Nisl tincidunt eget nullam non nisi est sit amet facilisis. Fermentum et sollicitudin ac orci phasellus egestas. Maecenas ultricies mi eget mauris pharetra et ultrices neque ornare. Pharetra magna ac placerat vestibulum lectus. Eu feugiat pretium nibh ipsum consequat nisl vel pretium. Urna condimentum mattis pellentesque id nibh. Ut morbi tincidunt augue interdum velit euismod. Potenti nullam ac tortor vitae purus faucibus ornare suspendisse. Mi eget mauris pharetra et ultrices neque ornare aenean. Ipsum nunc aliquet bibendum enim facilisis gravida neque convallis. Augue mauris augue neque gravida in fermentum et. Aenean vel elit scelerisque mauris pellentesque pulvinar. Mauris a diam maecenas sed enim. Suspendisse interdum consectetur libero id faucibus nisl tincidunt eget nullam. Lorem donec massa sapien faucibus et molestie. Dui nunc mattis enim ut tellus elementum.

​Fenwick & West is representing Audentes Therapeutics, Inc. (NASDAQ: BOLD) in its pending acquisition by Astellas Pharma Inc. (TSE: 4503) at a price of $60.00 per share in cash, representing a total equity value of approximately $3 billion.

Audentes is a leading AAV-based genetic medicines company focused on developing and commercializing innovative products for serious rare neuromuscular diseases. More information about the acquisition can be obtained from the company announcement​.

The Fenwick transaction team is being led by Fenwick partners Effie Toshav, Doug Cogen, David Michaels and Stefano Quintini. The team also includes corporate counsel Nicolas H.R. Dumont and associates Maureen Montgomery, Amy Zhang, Ryan Mitteness, Alice Lin, Sawyer Li, Michael Ohta, Annie Omata, Mitchell Duncombe and Alan Huang, and law clerks Jared Leung and Karin Hjorth; executive compensation and employee benefits partners Matthew Cantor and Gerald Audant and associate Corinne Nhaissi; intellectual property and technology transactions associates Jennifer Yoon, Gregory Hopewell, Sophia Chen, Pinar Bailey and Sang Kwon, and law clerk Brandon Cheung; securities litigation associate Vincent Barredo; antitrust partner Mark Ostrau; and tax partner William Skinner and associate Ora Grinberg.

Lobortis scelerisque fermentum dui faucibus in ornare quam viverra orci. Aliquet porttitor lacus luctus accumsan tortor posuere ac. Elementum pulvinar etiam non quam. Ut faucibus pulvinar elementum integer enim neque volutpat ac. Suspendisse potenti nullam ac tortor vitae purus faucibus. Lorem sed risus ultricies tristique. Viverra accumsan in nisl nisi. Cursus turpis massa tincidunt dui. Scelerisque eleifend donec pretium vulputate. Dignissim enim sit amet venenatis urna cursus. Risus nec feugiat in fermentum posuere urna nec tincidunt. Ut aliquam purus sit amet luctus venenatis lectus. Amet purus gravida quis blandit. In nulla posuere sollicitudin aliquam ultrices. Eu augue ut lectus arcu. Felis eget velit aliquet sagittis id consectetur purus. Magna sit amet purus gravida quis blandit turpis cursus in. Tristique risus nec feugiat in fermentum posuere urna nec tincidunt. Id donec ultrices tincidunt arcu non sodales neque.​